A review of the Human Insulin Market Share shows that three global giants—Novo Nordisk, Sanofi, and Eli Lilly—control the vast majority of the global supply. However, the landscape is changing as companies like Biocon and Viatris gain significant ground with biosimilar products. This increased competition is finally starting to drive down prices for the end consumer, particularly in the United States.

FAQ

• Who are the top insulin producers? The market is led by Novo Nordisk (Denmark), Eli Lilly (USA), and Sanofi (France).

• What is a biosimilar? A biosimilar is a biological product that is highly similar to an already approved "reference" biologic, offering similar safety and efficacy at a lower cost.